Ajinomoto (2802) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
2 Feb, 2026Executive summary
Achieved record Q1 revenue of ¥365.5 billion, up 7.7% year-over-year, with business profit at ¥43.0 billion, up 7% excluding Forge acquisition impact.
Profit attributable to owners declined to ¥23.9 billion, 88% of prior year, mainly due to a temporary overseas withholding tax increase from fund repatriation.
Strategic investments increased company-wide expenses in Q1, aligned with the 2030 Roadmap, but full-year expenses are expected to remain within forecast.
No revision to the full-year forecast announced in May 2024.
Financial highlights
Sales revenue: ¥365.5 billion, 107.7% of Q1 last year; 102.3% excluding currency impact.
Business profit: ¥43.0 billion, up 0.5% year-over-year; up 7% excluding Forge.
Gross profit improved by ¥9.5 billion year-over-year, with gross profit at ¥133.4 billion.
Operating profit was ¥40.8 billion, up from ¥40.6 billion year-over-year.
Basic EPS was ¥46.98, down from ¥51.77 year-over-year.
Outlook and guidance
Full-year profit guidance unchanged; company expects gradual improvement in profit and sales from Q2 onward, especially in CDMO and functional materials.
Price hikes in domestic seasonings and coffee to support profit recovery in coming quarters.
Dividend forecast for FY2025 is ¥80.00 per share, up from ¥74.00 in FY2024.
Latest events from Ajinomoto
- Integrated sustainability and innovation drive growth, decarbonization, and value creation.2802
Investor Day 202616 Mar 2026 - Record sales and profit, raised full-year outlook, and capital gains from asset sales.2802
Q3 20265 Feb 2026 - Record sales and profit growth drove forecast upgrades and major shareholder returns.2802
Q2 202516 Jan 2026 - Record sales and profit growth led by overseas, healthcare, and currency gains amid cost pressures.2802
Q3 20259 Jan 2026 - Profit attributable to owners rose 2% as H1 results were flat, with strong H2 recovery expected.2802
Q2 202610 Dec 2025 - Succession planning and strategic board evolution drive bold 2030 growth and sustainability targets.2802
Investor Day 20254 Dec 2025 - Business profit up 9.7% to ¥47.2bn, led by Functional Materials and Healthcare growth.2802
Q1 202623 Nov 2025 - Record sales and profit, with robust FY2025 growth, major buyback, and 2-for-1 stock split.2802
Q4 202518 Nov 2025 - Medical food sales set to double by 2030, driven by innovation, global reach, and new markets.2802
Investor update14 Nov 2025